The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Eli Lilly & Co. said Thursday ... weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker’s stock LLY rose 0.5% in regular trading ...

Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

Some doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures. A higher portion of muscle can also help patients keep weight off for ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. Here are two important insights from that call that should excite investors about ...